Biotech Values

[DewDiligence]

Re: RVNC /SAKURA-3 enrollment/retreatment

The number of trial sites doubled (from 30 to 61) from the 3/1/17 trial listing (https://www.clinicaltrials.gov/ct2/history/NCT03004248?V_2=View#StudyPageTop ) to the 12/4/17 trial listing (https://www.clinicaltrials.gov/ct2/history/NCT03004248?V_4=View#StudyPageTop ).

Of the 61 trial sites, 56 are in the US and 5 are in Canada.

Additionally, CEO Dan Browne said on a recent webcast that a larger proportion of SAKURA-3 patients than originally expected opted to be treated with RT002 a second time.